A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis-Reference-Cited by-同舟云学术

A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis

Published:2022-10 Issue: Volume:380 Page:104592
ISSN:0008-8749
Container-title:Cellular Immunology
language:en
Short-container-title:Cellular Immunology

Author:

Lopes Valentim Di Paschoale Ostolin Thais,Rodrigues Gusmão Miriã,Augusto Siqueira Mathias Fernando,Mirelle de Oliveira Cardoso Jamille,Mendes Roatt Bruno,Dian de Oliveira Aguiar-Soares Rodrigo,Conceição Ruiz Jeronimo,de Melo Resende Daniela,Cristiane Fortes de Brito Rory,Barbosa Reis Alexandre

Publisher

Elsevier BV

Subject

Immunology

Reference67 articles.

1. The use of genomics in microbial vaccine development;Bambini;Drug Discovery Today,2009

2. Possibilities and challenges for developing a successful vaccine for leishmaniasis;Srivastava;Parasites Vectors,2016

3. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis;Duarte;Rev. Soc. Bras. Med. Trop.,2016

4. A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons;Oliva;PLoS Negl.Trop. Dis.,2014

5. Evaluation of canine leishmaniosis vaccine CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area-A randomized controlled trial;Velez;Acta Trop.,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leishmania vaccine development: A comprehensive review;Cellular Immunology;2024-05

2. Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis species;Experimental Parasitology;2024-05

3. CD4+ Th1 and Th17 responses and multifunctional CD8 T lymphocytes associated with cure or disease worsening in human visceral leishmaniasis;Frontiers in Immunology;2024-02-12

4. The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice;Acta Tropica;2023-10

5. Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis;Parasitology Research;2023-09-28